Table of Contents
- Clinical trials overview
- Who the trials include
- Trial phases and study designs
- Main outcomes being measured
- Conditions being studied
- Important patient terms
Clinical trials overview
These trials study Tremelimumab in many cancer settings, often together with durvalumab and sometimes with surgery, radiation, chemotherapy, or other local treatments.[1][2][3] The main purpose is to see whether these treatment plans are safe and whether they help control cancer better than the comparison treatment or usual care.[1][4]
Several studies are already Authorised, and some are Completed.[1][3] The trials cover both earlier and later stages of research, so the questions range from basic safety and feasibility to survival and cancer control.[5][6]
Who the trials include
The studies include many different patient groups, depending on the cancer type and treatment goal.[1][7] Some trials include adults with advanced or unresectable cancer, such as advanced hepatocellular carcinoma, metastatic urothelial cancer, or unresectable malignant mesothelioma.[4][8][9]
Other trials focus on people whose cancer can still be removed with surgery, such as resectable gastric cancer, oral cavity cancer, or resectable hepatocellular carcinoma.[5][10][11] A few studies also include children and young adults with advanced solid tumors.[12]
Some trials are limited to special clinical situations, such as patients who have not had prior systemic therapy, people with microsatellite instability, or patients with cancer that has not progressed after chemoradiation.[2][5][13]
Trial phases and study designs
Most of the Tremelimumab studies in the source data are Phase 2 or Phase 3 trials.[1][4][6] Phase 2 trials usually look at early signs that the treatment works, while Phase 3 trials compare treatments in larger groups and focus on stronger proof of benefit.[4][6]
There are also Phase 1 studies, which mainly check safety, feasibility, and early biological effects.[5][10] For example, one Phase 1 study tests bronchoscopic injection of Tremelimumab in early-stage non-small cell lung cancer, and another Phase 1 study in children and young adults looks at safety and dose-finding.[10][12]
Some studies are randomized, which means patients are assigned by chance to different treatment groups.[4][8] Others are open-label, meaning both the research team and the patient know which treatment is being given.[4]
Main outcomes being measured
The most common outcome is overall survival, which means how long patients live after randomization or study start.[4][8][14] Several large studies in hepatocellular carcinoma, urothelial cancer, lung cancer, and mesothelioma use this as a main endpoint.[4][8][14]
Other important outcomes include progression-free survival, which measures how long the cancer stays under control, and objective response rate, which shows how many patients have a meaningful tumor shrinkage on scans.[6][9][5] Some studies also measure recurrence-free survival, disease-free survival, or event-free survival, which are ways to track whether the cancer returns or gets worse after treatment.[1][11][15]
Safety is also a major endpoint in many trials, including counts of adverse events, serious adverse events, dose-limiting toxicities, and treatment stopping because of side effects.[1][5][11] Some trials add detailed tests such as scans, lab tests, ECGs, vital signs, pathology review, or tumor tissue markers like CD8 infiltration and ctDNA status.[1][5][10]
Conditions being studied
Hepatocellular carcinoma is the most common cancer type in the trial list, with several studies testing Tremelimumab in advanced, locoregional, intermediate-stage, resectable, unresectable, or high-burden disease.[4][6][15][16] These trials examine different treatment settings, including first-line therapy, perioperative treatment, and combinations with TACE, SIRT, ablation, or hepatic arterial infusion.[6][15][16]
Bladder and urinary tract cancers are also studied, including muscle-invasive bladder cancer and unresectable locally advanced or metastatic urothelial cancer.[1][8] In these studies, Tremelimumab is tested with durvalumab and sometimes with chemotherapy or surgery, with survival and event-free survival as key outcomes.[1][8]
Other cancers in the source data include cholangiocarcinoma and biliary tract cancer, non-small cell lung cancer, small-cell lung cancer, renal cell carcinoma, malignant mesothelioma, gastric cancer, squamous cell carcinoma of the oral cavity, colorectal cancer, endometrial cancer, and several metastatic squamous cancers treated with radiotherapy.[2][5][9][5][10][12][13][17]
Important patient terms
Neoadjuvant therapy means treatment given before surgery, often to shrink the tumor or make surgery more effective.[2][5] Adjuvant therapy means treatment given after surgery to lower the chance that cancer returns.[11]
Resectable means the tumor can be removed by surgery, while unresectable means surgery cannot remove it completely or safely.[4][9] Metastatic means the cancer has spread to other parts of the body.[5][7]
Microsatellite instability is a tumor feature used to select some patients for the gastric cancer study, and ctDNA means circulating tumor DNA, a blood test that can help track cancer after treatment.[5] RECIST and mRECIST are scan-based rules used to measure how tumors respond to treatment.[6][5]
